Ness Seth L, Manyakov Nikolay V, Bangerter Abigail, Lewin David, Jagannatha Shyla, Boice Matthew, Skalkin Andrew, Dawson Geraldine, Janvier Yvette M, Goodwin Matthew S, Hendren Robert, Leventhal Bennett, Shic Frederick, Cioccia Walter, Pandina Gahan
Neuroscience Therapeutic Area, Janssen Research and Development, Titusville, NJ, United States.
Computational Biology, Discovery Sciences, Janssen Research and Development, Beerse, Belgium.
Front Neurosci. 2017 Sep 26;11:517. doi: 10.3389/fnins.2017.00517. eCollection 2017.
To test usability and optimize the Janssen Autism Knowledge Engine (JAKE®) system's components, biosensors, and procedures used for objective measurement of core and associated symptoms of autism spectrum disorder (ASD) in clinical trials. A prospective, observational study of 29 children and adolescents with ASD using the JAKE system was conducted at three sites in the United States. This study was designed to establish the feasibility of the JAKE system and to learn practical aspects of its implementation. In addition to information collected by web and mobile components, wearable biosensor data were collected both continuously in natural settings and periodically during a battery of experimental tasks administered in laboratory settings. This study is registered at clinicaltrials.gov, NCT02299700. Feedback collected throughout the study allowed future refinements to be planned for all components of the system. The Autism Behavior Inventory (ABI), a parent-reported measure of ASD core and associated symptoms, performed well. Among biosensors studied, the eye-tracker, sleep monitor, and electrocardiogram were shown to capture high quality data, whereas wireless electroencephalography was difficult to use due to its form factor. On an exit survey, the majority of parents rated their overall reaction to JAKE as positive/very positive. No significant device-related events were reported in the study. The results of this study, with the described changes, demonstrate that the JAKE system is a viable, useful, and safe platform for use in clinical trials of ASD, justifying larger validation and deployment studies of the optimized system.
为测试用于在临床试验中客观测量自闭症谱系障碍(ASD)核心及相关症状的扬森自闭症知识引擎(JAKE®)系统的组件、生物传感器和程序的可用性并进行优化。在美国的三个地点对29名患有ASD的儿童和青少年进行了一项使用JAKE系统的前瞻性观察性研究。本研究旨在确定JAKE系统的可行性并了解其实施的实际情况。除了通过网络和移动组件收集的信息外,还在自然环境中连续收集可穿戴生物传感器数据,并在实验室环境中进行的一系列实验任务期间定期收集。本研究已在clinicaltrials.gov上注册,编号为NCT02299700。在整个研究过程中收集的反馈意见为系统的所有组件的未来改进提供了规划依据。自闭症行为量表(ABI),一种由家长报告的ASD核心及相关症状的测量工具,表现良好。在所研究的生物传感器中,眼动仪、睡眠监测器和心电图显示能够捕获高质量数据,而无线脑电图由于其外形因素难以使用。在一项退出调查中,大多数家长对JAKE的总体反应评为积极/非常积极。该研究中未报告与设备相关的重大事件。本研究的结果,以及所描述的变化,表明JAKE系统是一个可行、有用且安全的平台,可用于ASD的临床试验,为优化系统的更大规模验证和部署研究提供了依据。